Data from prospective clinical trials have confirmed the high levels of PD-L1 expression on sRCC of clear-cell type, with ≥50% of patients displaying PD-L1 expression ≥1% on tumor cells [34] or immune-infiltrating cells [35,36]. The gene discussed is CD274; the disease is neoplasm.